The value of approved therapies for pulmonary arterial hypertension

American Heart Journal

Volumn 153, Issue 6, 2007, Pages 889-890

  Rich, Stuart ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN;

CLINICAL TRIAL; EDITORIAL; FOLLOW UP; HUMAN; MEDICAL LITERATURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; WORLD HEALTH ORGANIZATION;

CALCIUM CHANNEL BLOCKERS; EPOPROSTENOL; EXERCISE THERAPY; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; META-ANALYSIS; RESEARCH DESIGN;

EID: 34249294002     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.03.001     Document Type: Editorial

References (14)

1. Macchia A., Marchioli R., Marfisi R.M., et al. A meta-analysis of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 153 (2007) 1037-1047
2. Humbert M., Sitbon O., and Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 351 (2004) 1425-1436
3. Hoeper M.M., Oudiz R.J., Peacock A., et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 43 (2004) 48S-55S
4. Frost A.E., Langleben D., Oudiz R., et al. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vasc Pharmacol 43 (2005) 36-39
5. Olsson L.G., Swedberg K., Clark A.L., et al. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J 26 (2005) 778-793
6. Wu G., Sanderson B., and Bittner V. The 6-minute walk test: how important is the learning effect?. Am Heart J 146 (2003) 129-133
7. Newman J.H., and Robbins I.M. Exercise training in pulmonary hypertension: implications for the evaluation of drug trials. Circulation 114 (2006) 1448-1449
8. Rich S. The current treatment of pulmonary arterial hypertension: time to redefine success. Chest 130 (2006) 1198-1202
9. Badesch D.B., Abman S.H., Ahearn G.S., et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 35S-62S
10. Rich S., Kaufman E., and Levy P. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 (1992) 76
11. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111 (2005) 3105-3111
12. Mereles D., Ehlken N., Kreuscher S., et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 114 (2006) 1482-1489
13. Barst R., Rubin L., Long W., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334 (1996) 296-301
14. Barst R., McGoon M., McLaughlin V., et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 2119-2125